Woodline Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-170,848
Closed -$19.8M 725
2023
Q3
$19.8M Sell
170,848
-221,915
-57% -$23.8M 0.23% 133
2023
Q2
$40.4M Buy
392,763
+28,029
+8% +$2.96M 0.48% 51
2023
Q1
$39.8M Buy
364,734
+66,985
+22% +$7.4M 0.54% 38
2022
Q4
$33.9M Sell
297,749
-2,028,914
-87% -$169M 0.45% 49
2022
Q3
$144M Buy
2,326,663
+2,088,635
+877% +$146M 2.01% 2
2022
Q2
$19M Sell
238,028
-145,260
-38% -$13.8M 0.29% 107
2022
Q1
$40.3M Sell
383,288
-499,815
-57% -$48.7M 0.65% 30
2021
Q4
$95.2M Sell
883,103
-201,110
-19% -$21.9M 1.36% 7
2021
Q3
$119M Buy
1,084,213
+4
+0% +$415 1.94% 3
2021
Q2
$102M Buy
1,084,209
+627,338
+137% +$57.7M 1.89% 6
2021
Q1
$42M Buy
456,871
+312,210
+216% +$26.3M 0.93% 24
2020
Q4
$10.6M Sell
144,661
-790,942
-85% -$58.8M 0.28% 109
2020
Q3
$72.7M Sell
935,603
-486,371
-34% -$33.5M 2.38% 5
2020
Q2
$79M Buy
1,421,974
+148,480
+12% +$6.35M 3.13% 3
2020
Q1
$37.7M Sell
1,273,494
-846,662
-40% -$28.6M 2.69% 6
2019
Q4
$76.8M Buy
+2,120,156
New +$65M 3.14% 2

Other funds holding HZNP

Woodline Partners's HZNP Position: Q4 2023 in Review

Woodline Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 170,848 shares — an estimated $19.8M sold.

Woodline Partners first reported a position in HZNP in Q4 2019 and held it in 16 quarters. The position peaked at $144M in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Woodline Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Woodline Partners sold 170,848 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $19.8M.
  • Woodline Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 16 quarters.
  • Woodline Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $144M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Woodline Partners's 13F filing for Q4 2023, filed 14 Feb 2024.